Conmed CORP

CONMED Corporation announced second quarter 2026 financial results, showing modest sales growth and a significant increase in adjusted diluted EPS, while updating full-year guidance.

CONMED Corporation announced the appointment of John E. Gallagher as its new Executive Vice President and Chief Financial Officer, effective July 15, 2026.

CONMED Corporation announced on June 3, 2026, that it has entered into agreements to repurchase approximately $645.2 million of its 2.25% Convertible Senior Notes due 2027.

CONMED Corporation announced the First Omnibus Amendment and Increased Facility Activation Notice, amending its credit agreement to secure an additional $450 million in delayed draw term loans.

CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026, expanding the board to nine members.

CONMED Corporation announced first quarter 2026 financial results, with sales down 1.3% year-over-year due to product line exits, but raised its full-year organic revenue growth outlook.

CONMED Corporation announced its second quarter 2026 financial results, showing modest revenue growth driven by its Orthopedic Surgery segment, while navigating strategic divestitures and debt management.

CONMED Corporation announced its first quarter 2026 financial results, reporting a slight decrease in net sales driven by the exit from certain gastroenterology product lines, while gross profit margins improved.

CONMED Corporation reported increased net sales for Q3 2025 and the nine months ended September 30, 2025, but experienced significant declines in net income and gross profit margins due to higher costs, inventory write-offs, and advisory/consulting fees.

CONMED Corporation reported a significant drop in second-quarter net income and diluted EPS despite modest revenue growth, primarily due to increased selling and administrative expenses and unfavorable contingent consideration adjustments.

CONMED Corporation's Q1 2025 net sales increased by 2.9% year-over-year, but net income significantly decreased.

CONMED Corporation's third quarter results show a significant increase in net income and improved gross profit margins, driven by growth in both orthopedic and general surgery product lines.

CONMED Corporation reported a 5.2% increase in net sales for 2025, driven by growth in orthopedic and general surgery, alongside strategic portfolio optimization and a dividend suspension.

CONMED Corporation's 2024 annual report reveals a 5.0% increase in net sales, driven by growth in both orthopedic and general surgery product lines.

CONMED Corporation's 10-K filing details the terms of its common stock, including dividend, voting, and liquidation rights, as well as anti-takeover provisions.

John E Gallagher, Executive Vice President & CFO of CONMED Corp, reported multiple transactions in common stock on July 15, 2026.

CONMED Corp reports that Director Celine Christine Martin acquired 5,603 Restricted Stock Units (RSUs) on July 1, 2026, under the company's 2025 Long-Term Incentive Plan.

CONMED Corp Director Jeffrey B. Mirviss acquired 5,603 Restricted Stock Units (RSUs) on July 1, 2026, as part of the company's 2025 Long-Term Incentive Plan.

CONMED Corp reports that Director David M. Bronson acquired 668 shares of common stock through a transaction on June 2, 2026.

CONMED Corp reports a Form 4 filing detailing a transaction by Director LaVerne H. Council, involving the acquisition of common stock and restricted stock units.

CONMED Corp Director Kim Kelderman acquired 5,772 Restricted Stock Units (RSUs) on June 1, 2026, as part of the company's 2025 Long-Term Incentive Plan.

CONMED's 2026 proxy statement reveals 5.2% revenue growth in 2025, a dividend suspension, a $150M share repurchase, and significant board and executive leadership transitions.

CONMED provides additional details on its equity strategy, emphasizing its reliance on stock options and adjusted dilution levels, to garner support for the 2025 Long-Term Incentive Plan.

CONMED Corporation will hold its annual meeting of stockholders on May 20, 2025, to vote on key proposals including the election of directors, executive compensation, and the ratification of the company's auditor.

CONMED Corporation's proxy statement highlights a CEO transition, board changes, and strategic priorities for 2025, including resolving supply chain issues and focusing on high-growth platforms.

CONMED Corporation will hold its annual meeting of stockholders on May 22, 2024, to elect directors, conduct an advisory vote on executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as its independent auditor.

CONMED Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, executive compensation, and auditor ratification.

Vanguard Capital Management has reported beneficial ownership of 5.25% of CONMED Corp's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 6.87% in CONMED Corp's common stock as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in CONMED Corp following an internal realignment, with subsidiaries now reporting holdings separately.

Capital Research Global Investors has filed an Amendment No. 3 to its Schedule 13G, disclosing a 3.3% beneficial ownership in CONMED Corp. common stock.

Fuller & Thaler Asset Management, Inc. has disclosed a 5.63% beneficial ownership stake in Conmed Corp, totaling 1,740,630.07 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 15.1% beneficial ownership stake in CONMED Corp's common stock as of June 30, 2025.